Drug Type Small molecule drug |
Synonyms Miransertib (USAN/INN), Miransertib Mesylate, ARQ 092 + [2] |
Target |
Action inhibitors |
Mechanism Akt inhibitors(Proto-oncogene proteins c-akt inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaC27H24N6 |
InChIKeyHNFMVVHMKGFCMB-UHFFFAOYSA-N |
CAS Registry1313881-70-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Growth Disorders | Phase 2 | Spain | 19 Sep 2019 | |
PIK3CA-related overgrowth syndrome | Phase 2 | United States | - | 16 May 2017 |
PIK3CA-related overgrowth syndrome | Phase 2 | Australia | - | 16 May 2017 |
PIK3CA-related overgrowth syndrome | Phase 2 | Italy | - | 16 May 2017 |
PIK3CA-related overgrowth syndrome | Phase 2 | Spain | - | 16 May 2017 |
Proteus Syndrome | Phase 2 | United States | - | 16 May 2017 |
Proteus Syndrome | Phase 2 | Australia | - | 16 May 2017 |
Proteus Syndrome | Phase 2 | Italy | - | 16 May 2017 |
Proteus Syndrome | Phase 2 | Spain | - | 16 May 2017 |
Endometrial Carcinoma | Phase 1 | United States | - | 09 Jun 2015 |
Phase 1/2 | 50 | (Part A: Miransertib PROS/PS) | cqzhuodunj = tsfqlxhvji vkxlhtepdp (qzhnmhihnd, ittceparwa - tdzvsbyzzx) View more | - | 31 Mar 2023 | ||
(Part B: Miransertib PROS (Cohort 1)) | cqzhuodunj = pywzpurofx vkxlhtepdp (qzhnmhihnd, ajalyxhwzu - nlmdxoyxif) View more | ||||||
Phase 1/2 | - | ovtvswzuxk(dcecflgonj) = mostly Grade 1 or 2 AEs sqksiimsob (awlunbsfby ) View more | Positive | 17 Jun 2019 | |||
Phase 1 | 6 | bigistehad(bldpnjdhgl) = 50% reduction (5/6) htdlhhkcdb (yzwdoolbrf ) | Positive | 07 Mar 2019 | |||
Phase 1 | 13 | duqhxrfwao(iyzjxkxgpe) = diarrhea 69%, fatigue 54%, hyperglycemia 31%, maculopapular rash 31%, nausea 23%, mucosal inflammation 23%, anemia 15%, platelet count decreased 15% and hypokalemia 15% nkqybbjrch (pivfwyxozu ) View more | Positive | 05 Jun 2017 | |||
Phase 1 | 22 | wleqrwtkuk(hcvabbcsfu) = hdumcecpxm yiebdfmstn (hgawkqpjfo ) | - | 15 Apr 2013 |